Department of Clinical Oncology, Zealand University Hospital, 4000 Roskilde, Denmark.
Department of Nutrition, Exercise and Sports, University of Copenhagen, 2200 Frederiksberg, Denmark.
Nutrients. 2023 Jul 1;15(13):3014. doi: 10.3390/nu15133014.
Taste alteration is a common adverse effect of chemotherapy. This study aimed to investigate the effect of cannabidiol (CBD) on Lean Body Mass (LBM), and taste alterations during oxaliplatin- or paclitaxel-based chemotherapy.
LBM was estimated by bioelectrical impedance analysis (BIA), and taste perception was evaluated by a randomized sensory test of six samples: sweet, salt, and umami, all in weak and strong concentrations. Taste perceptions were scored on visual analog scales. Patients in the intervention group received oral CBD 300 mg/day for 8 days; patients in the control group did not. Patients were followed for three cycles of chemotherapy.
Twenty-two/ten patients (intervention/control group) were eligible. No effects on LBM were demonstrated. At baseline, the control group was able to differentiate between weak and strong saltiness and weak and strong sweetness but lost this ability after three cycles of chemotherapy. At baseline, the intervention group was unable to differentiate between the concentrations but gained the ability to significantly differentiate between weak and strong sweetness ( = 0.03) and weak and strong saltiness ( = 0.04) after three cycles of chemotherapy and treatment with CBD.
CBD may improve patients' ability to differentiate taste strengths during chemotherapy.
味觉改变是化疗的常见不良反应。本研究旨在探讨大麻二酚（CBD）对基于奥沙利铂或紫杉醇化疗期间去脂体重（LBM）和味觉改变的影响。
通过生物电阻抗分析（BIA）估计 LBM，并通过随机六种样本的感官测试评估味觉感知：甜味、咸味和鲜味，均为弱和强浓度。味觉感知通过视觉模拟量表进行评分。干预组患者接受 CBD 300mg/天，持续 8 天；对照组患者不接受治疗。患者接受三个化疗周期的随访。
22/10 名患者（干预组/对照组）符合条件。未显示 CBD 对 LBM 有影响。在基线时，对照组能够区分弱和强咸味以及弱和强甜味，但在三个化疗周期后失去了这种能力。在基线时，干预组无法区分浓度，但在接受 CBD 治疗和三个化疗周期后，能够显著区分弱和强甜味（=0.03）和弱和强咸味（=0.04）。
CBD 可能改善患者在化疗期间区分味觉强度的能力。
